Evidence map›Paper›PMID 25076060›Full record

ArticleMarine drugs2014

Marinopyrrole derivatives with sulfide spacers as selective disruptors of Mcl-1 binding to pro-apoptotic protein Bim.

Chunwei Cheng, Yan Liu, Maria E Balasis, Thomas P Garner, Jerry Li, Nicholas L Simmons, Norbert Berndt, Hao Song, Lili Pan, Yong Qin and 4 more

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-xChembiochem : a European journal of chemical biology · 2022
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Chunwei ChengKey Laboratory of Drug Targeting and Drug Delivery Systems of the Ministry of Education and State Key Laboratory of Biotherapy, Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. chengchunwei666@163.com.
Yan LiuDepartment of Drug Discovery and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. yan.liu@unmc.edu.
Maria E BalasisDepartment of Drug Discovery and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. maria.balasis@moffitt.org.
Thomas P GarnerDepartments of Biochemistry and Medicine, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, 1300 Morris Park Avenue, Forchheimer G46, Bronx, NY 10461, USA. thomas.garner@einstein.yu.edu.
Jerry LiDepartment of Drug Discovery and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. jerry.li@ucsf.edu.
Nicholas L SimmonsDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. nsimmons@scripps.edu.
Norbert BerndtDepartment of Drug Discovery and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Norbert.berndt@moffitt.org.
Hao SongKey Laboratory of Drug Targeting and Drug Delivery Systems of the Ministry of Education and State Key Laboratory of Biotherapy, Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. haoright@163.com.
Lili PanKey Laboratory of Drug Targeting and Drug Delivery Systems of the Ministry of Education and State Key Laboratory of Biotherapy, Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. pande179@163.com.
Yong QinKey Laboratory of Drug Targeting and Drug Delivery Systems of the Ministry of Education and State Key Laboratory of Biotherapy, Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. qinyong@cqu.edu.cn.
K C NicolaouDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. kcn@rice.edu.
Evripidis GavathiotisDepartments of Biochemistry and Medicine, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, 1300 Morris Park Avenue, Forchheimer G46, Bronx, NY 10461, USA. evripidis.gavathiotis@einstein.yu.edu.
Said M SebtiDepartment of Drug Discovery and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. said.sebti@moffitt.org.
Rongshi LiDepartment of Drug Discovery and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. rongshi.li@unmc.edu.
Moffitt Cancer Center · USState Key Laboratory of BiotherapyAlbert Einstein College of Medicine · USNebraska Medical Center · USScripps Research Institute · USChongqing University · CNUniversity of South Florida · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
Small Molecule Activators of Pro-apoptotic BAX for Cancer TherapyR01CA178394 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GAVATHIOTIS, EVRIPIDIS · 2014 to 2024
$3.7M
Targeting BAX Oligomerization in Hematologic DiseaseR00HL095929 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GAVATHIOTIS, EVRIPIDIS · 2011 to 2013
$716k
NCI NIH HHS P30 CA013330NCI NIH HHS P30CA013330-39S1NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA178394NHLBI NIH HHS R00 HL095929
6 · The paper itself

Abstract

A series of novel marinopyrroles with sulfide and sulphone spacers were designed and synthesized. Their activity to disrupt the binding of the pro-apoptotic protein, Bim, to the pro-survival proteins, Mcl-1 and Bcl-xL, was evaluated using ELISA assays. Fluorescence-quenching (FQ) assays confirmed the direct binding of marinopyrroles to Mcl-1. Benzyl- and benzyl methoxy-containing sulfide derivatives 4 and 5 were highly potent dual Mcl-1/Bim and Bcl-xL/Bim disruptors (IC50 values of 600 and 700 nM), whereas carboxylate-containing sulfide derivative 9 exhibited 16.4-fold more selectivity for disrupting Mcl-1/Bim over Bcl-xL/Bim binding. In addition, a nonsymmetrical marinopyrrole 12 is as equally potent as the parent marinopyrrole A (1) for disrupting both Mcl-1/Bim and Bcl-xL/Bim binding. Some of the derivatives were also active in intact human breast cancer cells where they reduced the levels of Mcl-1, induced programd cell death (apoptosis) and inhibited cell proliferation.

Indexed as

ApoptosisApoptosis Regulatory ProteinsBcl-2-Like Protein 11bcl-X ProteinCell Line, TumorHumansMembrane ProteinsMyeloid Cell Leukemia Sequence 1 ProteinProtein BindingProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2PyrrolesSulfidesApoptosis Regulatory ProteinsBCL2L11 protein, humanBcl-2-Like Protein 11bcl-X ProteinMCL1 protein, humanMembrane ProteinsMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2PyrrolesSulfides

Identifiers

PMID25076060
PMCPMC4145318
OpenAlexW2102503292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.